‣ Patients must meet all the following inclusion criteria to be eligible for participation in this study:

• The patient provides written informed consent for the study.

• Willing to comply with the visit plans, treatment plans, and other requirements of the study schedule.

• Previous HPV16+ solid tumors.

• 18 to 75 years of age at the time of informed consent.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with no deterioration over the previous 2 weeks.

• Estimated life expectancy of more than 12 weeks.

• Previous HPV16 positive head and neck, cervical and other carcinoma patients with recurrent or metastatic disease, who have progressed after standard therapies, or for whom no further standard therapies are available.

• Patients should have at least 1 measurable lesion at baseline according to the definition of RECISTv1.1.

• Absolute neutrophil count ≥ 1.5 ×10\^9/L, without the use of granulocyte colony stimulating factors such as filgrastim within 2 weeks prior to study treatment. Platelet count ≥ 100 × 10\^9/L without transfusion within 2 weeks (≤ 14 days) prior to study treatment. Hemoglobin ≥ 9 g/dL without transfusion or erythropoietin within 2 weeks (≤ 14 days) prior to study treatment.

⁃ Aspartate transaminase and alanine aminotransferase ≤ 3 × upper limit of normal (ULN) (patients with liver metastasis \< 5 × ULN), and total bilirubin ≤ 1.5 × ULN (patients with Gilbert's Syndrome ≤ 3 × ULN).

⁃ Adequate renal function defined by either a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula) or serum creatinine \< 1.5 × ULN.

⁃ Prothrombin time ≤ 1.5 × ULN; activated partial thromboplastin time ≤ 1.5 × ULN; international normalized ratio ≤ 1.5 × ULN.

⁃ Left ventricular ejection fraction ≥ 50% measured by echocardiogram.

⁃ Females of childbearing potential and males whose partners are of childbearing potential agree to the use effective contraception from signing informed consent form to 90 days after the last dose of TI-0093 injection. The test results of HCG of females with childbearing potential should be negative within 7 days prior to the first dose of TI-0093 injection.